Moderna yesterday announced an updated timeline for its COVID-19 vaccine for children. According to Moderna, the Food and Drug Administration last week notified the drug maker that it may not complete its assessment of the company’s EUA request for children age 12 to 17 before January 2022. The delay is to evaluate recent international analyses of the risk of myocarditis after vaccination. As a result, Moderna said it will also delay requesting an EUA for its 50-microgram-dose version of the vaccine for 6- to 11-year-olds.

Related News Articles

Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…